+61 2 9905 0133
7/27 Dale Street Brookvale 2100 SYDNEY NSW, AUSTRALIA
Cellabs is a leading biotechnology company based in Sydney, Australia specialising in the design, development, and manufacture of immunodiagnostic kits for tropical and infectious diseases. Cellabs is the oldest private biotechnology company in Australia and continues to supply customers worldwide with superior quality products.
Cellabs has specifically targeted those diseases that afflict millions of people worldwide and was one of the first companies to provide diagnostics for malaria, cryptosporidiosis, giardiasis, and chlamydial diseases. Cellabs also has a long history of market leadership with a number of its products, most notably its antibody reagent for Cryptosporidium identification. The Crypto Cel Antibody Reagent became the first IFA reagent approved by the UK Drinking Water Inspectorate to enable water companies to comply with the new Drinking Water Regulations.
The Cellabs ELISA kits for malaria has become an important diagnostic tool in the areas of clinical, research and blood banking. Malaria Ag CELISA for HRP-2 is fast becoming the test of choice for drug sensitivity studies, a newly improved ultra-sensitive version of this test for low-level parasitaemia is now available. The Pan Malaria Antibody CELISA for antibody detection and Quantimal Ultra-sentisibe pLDH CELISA for antigen detection are fast becoming the test of choice for high volume screening and blood banking.
Cellabs products are available in three convenient formats; direct (DFA) and indirect (IFA) immunofluorescent assays, enzyme-linked immunosorbent assay (ELISA), and rapid diagnostic tests (RDT). All products are manufactured under the international IVD standard ISO13485:2016. We are continuing to develop new products to complement our existing product range through Research and Development.